Urethral injection for stress urinary incontinence: long-term results with dextranomer/hyaluronic acid copolymer

Int Urogynecol J Pelvic Floor Dysfunct. 2003 Nov;14(5):335-8; discussion 338. doi: 10.1007/s00192-003-1075-y. Epub 2003 Sep 13.

Abstract

Urethral injection is a convenient, minimally invasive means of treating stress urinary incontinence (SUI). We present long-term follow-up data from 20 patients originally recruited in 1994-95 (mean age 67 years) to receive urethral injection with dextranomer/hyaluronic acid (Dx/HA) copolymer. The majority of patients had failed previous therapy for SUI. If the first injection was unsuccessful, up to two further injections were offered. Only 3 patients (15%) failed to show a response to treatment. Sixteen women were reassessed during 2001 (4 had died of causes unrelated to the study treatment). A sustained response throughout the follow-up period was reported in 9/16 patients (57%), with incontinence recurring in just 4 (25%). None of the 7 patients with persistent or recurrent incontinence were cured by subsequent treatments, including surgery. In conclusion, urethral injection with Dx/HA copolymer offers promising long-term efficacy in the treatment of SUI, regardless of old age or failure to respond to previous therapy.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biocompatible Materials / administration & dosage*
  • Dextrans / administration & dosage*
  • Female
  • Follow-Up Studies
  • Humans
  • Hyaluronic Acid / administration & dosage*
  • Injections
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Urethra*
  • Urinary Incontinence, Stress / therapy*

Substances

  • Biocompatible Materials
  • Dextrans
  • dextranomer
  • Hyaluronic Acid